Amphotericin B chemical structure
Find information on thousands of medical conditions and prescription drugs.

Ambisome

Amphotericin B (Fungilin®, Fungizone®, Abelcet®, AmBisome®, Fungisome®, Amphocil®, Amphotec®) is a polyene antimycotic drug, used intravenously in systemic fungal infections. It was originally extracted from Streptomyces nodosus fungi. Currently the drug is available as plain Amphotericin B, as cholesteryl sulfate complex, as lipid complex, and as liposomal formulation. The latter formulations have been developed to improve tolerability for the patient but may show considerable pharmacokinetic characteristics compared to plain Amphotericin B. more...

Home
Diseases
Medicines
A
8-Hour Bayer
Abacavir
Abamectin
Abarelix
Abciximab
Abelcet
Abilify
Abreva
Acamprosate
Acarbose
Accolate
Accoleit
Accupril
Accurbron
Accure
Accuretic
Accutane
Acebutolol
Aceclidine
Acepromazine
Acesulfame
Acetaminophen
Acetazolamide
Acetohexamide
Acetohexamide
Acetylcholine chloride
Acetylcysteine
Acetyldigitoxin
Aciclovir
Acihexal
Acilac
Aciphex
Acitretin
Actifed
Actigall
Actiq
Actisite
Actonel
Actos
Acular
Acyclovir
Adalat
Adapalene
Adderall
Adefovir
Adrafinil
Adriamycin
Adriamycin
Advicor
Advil
Aerobid
Aerolate
Afrinol
Aggrenox
Agomelatine
Agrylin
Airomir
Alanine
Alavert
Albendazole
Alcaine
Alclometasone
Aldomet
Aldosterone
Alesse
Aleve
Alfenta
Alfentanil
Alfuzosin
Alimta
Alkeran
Alkeran
Allegra
Allopurinol
Alora
Alosetron
Alpidem
Alprazolam
Altace
Alteplase
Alvircept sudotox
Amantadine
Amaryl
Ambien
Ambisome
Amfetamine
Amicar
Amifostine
Amikacin
Amiloride
Amineptine
Aminocaproic acid
Aminoglutethimide
Aminophenazone
Aminophylline
Amiodarone
Amisulpride
Amitraz
Amitriptyline
Amlodipine
Amobarbital
Amohexal
Amoxapine
Amoxicillin
Amoxil
Amphetamine
Amphotec
Amphotericin B
Ampicillin
Anafranil
Anagrelide
Anakinra
Anaprox
Anastrozole
Ancef
Android
Anexsia
Aniracetam
Antabuse
Antitussive
Antivert
Apidra
Apresoline
Aquaphyllin
Aquaphyllin
Aranesp
Aranesp
Arava
Arestin
Arestin
Argatroban
Argatroban
Argatroban
Argatroban
Arginine
Arginine
Aricept
Aricept
Arimidex
Arimidex
Aripiprazole
Aripiprazole
Arixtra
Arixtra
Artane
Artane
Artemether
Artemether
Artemisinin
Artemisinin
Artesunate
Artesunate
Arthrotec
Arthrotec
Asacol
Ascorbic acid
Asmalix
Aspartame
Aspartic acid
Aspirin
Astemizole
Atacand
Atarax
Atehexal
Atenolol
Ativan
Atorvastatin
Atosiban
Atovaquone
Atridox
Atropine
Atrovent
Augmentin
Aureomycin
Avandia
Avapro
Avinza
Avizafone
Avobenzone
Avodart
Axid
Axotal
Azacitidine
Azahexal
Azathioprine
Azelaic acid
Azimilide
Azithromycin
Azlocillin
Azmacort
Aztreonam
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Uses

Oral preparations of amphotericin B are used to treat oral thrush; these are virtually nontoxic. The main i.v. use is in systemic fungal infections (e.g. in immunocompromised patients), and in visceral leishmaniasis. Aspergillosis, cryptococcus infections (e.g. meningitis) and candidiasis are treated with amphotericin B. It is also used empirically in febrile immunocompromised patients who do not respond to broad-spectrum antibiotics.

Method of action

As with other polyene antifungals, amphotericin B associates with ergosterol, a membrane chemical of fungi, forming a pore that leads to K+ leakage and fungal cell death. Recently, however, researchers found evidence that pore formation is not necessarily linked to cell death (i.e. Angewandte Chemie Int. Ed. Engl. 2004). The actual mechanism of action may be more complex and multi-faceted.

Side effects

Very often a most serious acute reaction after the infusion (1 to 3 hours later) is noted consisting of fever, shaking chills, hypotension, anorexia, nausea, vomiting, headache, dyspnea, and tachypnea. This reaction sometimes subsides with later applications of the drug and may in part be due to histamine liberation. An increase in prostaglandin-synthesis may also play a role. Often the most difficult decision has to be made, whether the fever is disease- or drug-related. In order to decrease the likelihood and severity of the symptoms, initial doses should be low and increased slowly. The liposomal preperation obviously has a lower incidence of the syndrome. Acetaminophen, pethidine, diphenhydramine and/or hydrocortisone have all be used to treat or prevent the syndrome, but the prophylactic use of these drugs should be limited.

Nephrotoxicity (kidney damage) is a major issue and can be severe and/or irreversible. It is much milder when amphotericin B is delivered in liposomes (AmBisome). Electrolyte imbalances (e.g. hypokalema and hypocalcemia) may also occur.

Increased liver enzymes and hepatotoxicity up to acute liver failure, several forms of anemia and other blood dyscrasias (leukopenia, thrombopenia), serious cardiac arrhythmias (including ventricular fibrillation), and cardiac failure have also been reported frequently. Skin reactions, including serious forms, are also possible.

Interactions

  • Flucytosine : Toxicity of Flucytosine increased and vice versa
  • Diuretics or Cisplatin : Increased renal toxicity and incrised risk of hypokalema
  • Corticosterioids : Increased risk of hypokalema
  • Cytostatic drugs : Increased risk of kidney damage, hypotension and bronchospasms.
  • Other nephrotoxic drugs : Increased risk of serious renal damage. Monitor patients closely.
  • Foscarnet, Ganciclovir, Tenofovir, Adefovir : Risk of hematological and renal side-effects of Amphotericin B increased.
  • Transfusion of Leukocytes : Risk of pulmonal (lung) damage. Space intervalls between the application of Amphotericin B and the transfusion and monitor pulmonal function.

Read more at Wikipedia.org


[List your site here Free!]


New Synthetic Antifungals Showing Promise - Brief Article - Statistical Data Included
From Family Pratice News, 1/15/00 by Bruce Jancin

ROCHESTER, MINN. -- Medicine may be on the verge of an explosion in new synthetic antifungal agents comparable to that seen in the antiviral arena in recent years.

A rich pharmaceutical pipeline makes this "a pretty exciting time in antifungal therapy. I think we're going to see some big changes," Dr. Michael R. Keating predicted at a dermatology meeting sponsored by the Mayo Foundation.

A boom in antifungal options is long overdue. "This is an area where we have a desperate need, a critical need, for new agents," stressed Dr. Keating, an infectious disease specialist at the Mayo Clinic.

That's because over the last few decades the population at risk for systemic mycoses has ballooned. The explanation is multifaceted, including greater use of organ transplantation, cancer chemotherapy immunomodulatory therapy for inflammatory disorders, and implanted prosthetic devices. And then there's the AIDS epidemic.

Meanwhile, significant resistance has emerged to the limited repertoire of existing agents, and important new systemic fungal pathogens have emerged in the last 10 years. For example, at many tertiary care centers, cases of candidiasis due to Candida albicans are now outnumbered by cases of fluconazole-resistant C. glabrata and C. krusei, he continued.

So what's on the horizon? Third-generation triazoles are, for one thing.

Furthest along in clinical trials is voriconazole; both oral and intravenous preparations are under intensive investigation. Voriconazole is a broad-spectrum agent that is very active against Aspergillus, Candida species, and important emerging pathogens such as Acreinonium, Scedosporium, and Fusarium. It is quite well tolerated, although 15% of treated patients experience a transient "flashing light" phenomenon, Dr. Keating said at the meeting, which was also sponsored by the Minnesota Dermatologic Society.

Nystatin is a drug that has managed to retain its antifungal activity despite decades of use. What's new here is the development of a liposomal form that is under investigation for systemic use.

Nikkomycin is an investigational chitin synthase inhibitor with "some real potential," in Dr. Keating's view Chitin is an essential component of the cell wall of yeasts and molds and therefore a great target for a novel agent. Yet nikkomycin appears to have only a limited spectrum of activity: It is active against Candida, Coccidioides, Blastomyces, and Histoplasma species. Combined with an azole, however, nikkomycin exhibits impressive synergy against these pathogens as well as against Aspergillus species.

Echinocandins and pneumocandins work by inhibiting glucan synthase, which produces glucan, another essential cell wall component of yeasts and molds. Merck, Eli Lilly, and other companies are now shepherding echinocandins and pneumocandins through phase II and III trials in the treatment of esophageal candidiasis, invasive candidiasis, and aspergillosis, Dr. Keating noted.

Echinocandins are active against Aspergillus and Canidida species; pneumocandins have a similar spectrum but in addition are active against Pneumocystis. Neither, however, is active against Cryptococcus--a real drawback, he said.

Allylamines and thiocarbamates inhibit the enzyme squalence epoxidase. This action interferes with production of ergosterol, an essential fungal cell wall component that's also the target of amphotericin. Terbinafine, the first allylamine on the market, has recently been shown to be effective against Sporothrix. "We may see expanded labeling for this drug," according to Dr. Keating.

But again, the exciting new finding for terbinafine is its apparent potent synergy in combination with other agents, including fluconazole and itraconazole, he added.

Pradimicins and benanomicins are broadspectrum antifungal agents with a unique action. They work by binding cell wall mannoproteins in a calcium-dependent manner. They appear safe thus far but are in a very early stage of development.

Three different lipid preparations of amphotericin B are now commercially available: Abelcet, AmBisome, and Amphotec. There's no question that the liposomal preparations are less nephrotoxic, generally safer, and better tolerated than conventional amphotericin B, Dr. Keating said. The big unanswered question is: Are they truly more effective?

The lack of data on relative efficacy makes it difficult to use these agents intelligently, particularly in light of their high cost. For example, the average wholesale price of AmBisome at a dose of 3 mg/kg is $506/day, or $7,084 for a 2-week course. At 5 mg/kg, a 2-week course costs $12,250. "And if we're treating aspergillosis we're talking 4-6 weeks of therapy," Dr. Keating noted.

Amphotec has only one labeled indication: treatment of invasive aspergillosis. But there are clinical data to suggest the agent also has efficacy against invasive candidiasis, cryptococcal infection, and neutropenic fever.

AmBisome is FDA approved for empiric therapy of presumed fungal infection in patients with neutropenic fever, as well as for aspergillosis, candidiasis, or cryptococcal infection refractory to or intolerant of conventional amphotericin B deoxycholate.

Abelcet is indicated for the treatment of invasive fungal infections where conventional amphotericin B is ineffective or not tolerated.

Look for greater use of combinations of existing and novel antifungal drugs as multidrug therapy comes under increasing formal scrutiny in clinical trials. For example, there are good data to show enhanced survival when patients with invasive aspergillosis receive a combination of amphotericin B and the nucleoside analog 5-flucytosine, compared with amphotericin B alone.

The same combination was earlier shown to be the treatment of choice for cryptococcal meningitis and other serious cryptococcal infections, he commented.

But the story of combination therapy is a complex one. Within infectious disease circles, there is a hotly debated theoretic concern about antagonism, which appears to be borne out by animal studies involving certain drug combinations.

For example, itraconazole and amphotericin B were antagonistic in animal models of aspergillosis, while fluconazole and amphotericin were synergistic in models of cryptococcal and candidal infection.

"I think this is a very confusing area that's probably going to have to be worked out agent by agent and organism by organism," Dr. Keating said.

COPYRIGHT 2000 International Medical News Group
COPYRIGHT 2001 Gale Group

Return to Ambisome
Home Contact Resources Exchange Links ebay